Integrin-Targeting Ligands for Serum-Stable RNAi Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in delivering cargo molecules, particularly oligonucleotide-based therapeutics, to specific cells and tissues, such as tumor cells, with a need for stable and effective targeting compounds that can selectively bind to integrins αvβ3 and αvβ5 for therapeutic delivery.
Innovation Solution
Development of integrin targeting ligands that have affinity for αvβ3 and αvβ5, which are conjugated to cargo molecules like RNAi agents, enabling selective delivery to integrin-expressing cells, including tumor cells, and maintaining stability in serum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional targeting compounds are used to deliver cargo molecules to specific cells, then delivery to desired cells is attempted, but the compounds lack stability in serum and fail to achieve effective selective binding
Solution Approach 1:
The patent modifies the chemical structure of integrin-binding compounds by incorporating specific functional groups and molecular configurations that enhance serum stability while preserving integrin affinity. This involves changing physical and chemical parameters of the targeting ligand to achieve both stability and effectiveness.
Solution Approach 2:
The invention creates composite structures by conjugating integrin-targeting ligands with cargo molecules (such as oligonucleotides, drugs, or imaging agents) through stable linkers. This composite approach ensures the targeting component remains stable in serum while the cargo is selectively delivered to integrin-expressing cells.
2Reliability
If integrin antagonists are used to inhibit integrin function, then angiogenesis inhibition is achieved, but clinical efficacy is insufficient and tumor progression is not effectively prevented
Solution Approach 1:
Instead of using free integrin antagonists that merely block integrin function, the patent employs integrin-targeting ligands as intermediaries that actively deliver cargo molecules (such as RNAi agents or therapeutic compounds) directly into integrin-expressing tumor cells. This mediator approach enables both integrin targeting and intracellular delivery of therapeutic payloads, achieving superior efficacy compared to simple antagonism.
3Reliability
If targeting ligands are conjugated to cargo molecules for selective delivery, then specific cell targeting is achieved, but the conjugation may reduce stability or binding affinity
Solution Approach 1:
The patent extracts the integrin-binding functional group from complex antibody structures and incorporates it into smaller, chemically stable small molecule ligands. This extracted approach allows the core targeting functionality to be preserved while eliminating the instability issues associated with larger biomolecular conjugates, enabling stable serum circulation and effective integrin binding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The integrin targeting ligands facilitate targeted delivery of therapeutic cargo molecules to integrin-expressing cells, enhancing treatment efficacy by inhibiting gene expression and treating diseases like clear cell renal carcinoma.
Implementation Method 1
compounds that have affinity for integrins, including αvβ3 and αvβ5, which can be employed as ligands to selectively direct compounds or other molecules to which they are attached to cells or tissues that express integrin αvβ3 and/or αvβ5
Data Source
AI summary
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and/or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.